Yumanity Therapeutics, INC.: insider trades · United States · SEC (Form 4)

About Yumanity Therapeutics, INC.

Yumanity Therapeutics, Inc. (ticker YMTX) is a U.S.-listed biotechnology company quoted on the NASDAQ market in the United States. Historically, the company focused on the discovery and development of disease-modifying therapies for neurodegenerative disorders, with research efforts centered on conditions such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Its principal executive offices are in Boston, Massachusetts, placing it within one of the major U.S. biopharma hubs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000119312521101509/d51046d10k.htm)) From a company-history perspective, Yumanity’s current public-market identity dates to a December 2020 merger in which Proteostasis Therapeutics changed its name to Yumanity Therapeutics and the trading symbol became YMTX. Since then, the company has undergone a significant strategic reset. In 2022, Yumanity announced a definitive asset sale agreement with Janssen for $26 million in cash, covering its lead clinical-stage candidate YTX-7739 as well as certain unpartnered neuroscience discovery assets and targets, alongside a planned merger with Kineta. That sequence of events materially changed the company’s operating profile and made Yumanity a more transaction-driven biotech story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000119312521101509/d51046d10k.htm)) Operationally, Yumanity was built around a neuroscience discovery platform rather than a commercial product franchise. Its core model relied on identifying biologically relevant disease mechanisms and advancing early-stage therapeutic programs, while also leveraging partnerships to extend the value of its intellectual property. One notable example was its collaboration with Merck on programs related to ALS and FTLD, which provided external validation for the platform. Before the asset sale, YTX-7739 was the most advanced program in the pipeline and had been developed for Parkinson’s disease. On a competitive basis, Yumanity should be viewed as a small-cap biotech competing through scientific innovation, licensing optionality, and strategic partnerships rather than through marketed products or scale manufacturing. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000119312520228587/d14103dex991.htm?utm_source=openai)) For international equity investors, the key takeaway is that YMTX has historically been a high-risk, event-driven life-sciences name. The company’s value proposition has depended on R&D milestones, licensing economics, and corporate transactions more than on recurring product revenue. Its geographic footprint has remained primarily U.S.-based, with Boston as its headquarters, although the company’s collaborations and scientific reach have been broader. Recent headline developments include the Janssen asset sale announcement and the planned Kineta merger, both of which signaled a major strategic pivot away from Yumanity’s original standalone neuroscience thesis. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017022024755/ymtx_1114_425.htm))